Patents by Inventor Marvin Rubenstein

Marvin Rubenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells
    Patent number: 5891858
    Abstract: Antisense polynucleotides to human transforming growth factor alpha (TGF-.alpha.) and the receptor for human epidermal growth factor (rEGF) are disclosed. Those polynucleotides are about 30 to about 50 bases in length and each hybridizes to about 10 to about 25 bases flanking the start codon for the gene encoding those proteins. Use of those antisense polynucleotides alone, together and mixed with an antibody combining site-containing molecule that binds to rEGF in treating human growth factor-sensitive cancerous tumors such as prostate tumors is also disclosed.
    Type: Grant
    Filed: October 17, 1996
    Date of Patent: April 6, 1999
    Assignee: Hektoen Institute for Medical Research
    Inventor: Marvin Rubenstein
  • Antisense polynucleotide inhibition of epidermal human growth factor receptor expression
    Patent number: 5610288
    Abstract: Antisense polynucleotides to human transforming growth factor alpha (TGF-.alpha.) and the receptor for human epidermal growth factor (rEGF) are disclosed. Those polynucleotides are about 30 to about 50 bases in length and each hybridizes to about 10 to about 25 bases flanking the start codon for the gene encoding those proteins. Use of those antisense polynucleotides alone, together and mixed with an antibody combining site-containing molecule that binds to rEGF in treating human growth factor-sensitive cancerous tumors such as prostate tumors is also disclosed.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: March 11, 1997
    Assignee: Hekton Institute for Medical Research
    Inventor: Marvin Rubenstein